Patents by Inventor Eric Konofal

Eric Konofal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MAZINDOL COMBINATION IN THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY
    Publication number: 20240108605
    Abstract: The present invention relates to the field of human health, and more particularly to the treatment of attention deficit/hyperactivity disorder (ADHD) with mazindol. The latter can be administered as monotherapy or in combination with one or more compounds, including psychostimulants, for the indication of ADHD and associated or co-morbid symptoms.
    Type: Application
    Filed: October 3, 2023
    Publication date: April 4, 2024
    Inventor: Eric KONOFAL
  • PHACETOPERANE FOR TREATING OF ATTENTION DEFICIT HYPERACTIVITY DISORDER
    Publication number: 20220054471
    Abstract: The invention relates to the treatment of an attention deficit hyperactivity disorder (ADHD) with alpha-phenyl(piperidin-2-yl)methanol, or the pharmaceutically acceptable salts and esters thereof, in particular the acetate derivative, more particularly dextrophacetoperane. The invention additionally provides a method of synthesis of the (S,S) enantiomer of alpha-phenyl(piperidin-2-yl)methanol as well as a method of synthesis of dextrophacetoperane.
    Type: Application
    Filed: November 8, 2021
    Publication date: February 24, 2022
    Inventors: Eric KONOFAL, Bruno FIGADERE
  • MAZINDOL COMBINATION IN THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY
    Publication number: 20210093614
    Abstract: The present invention relates to the field of human health, and more particularly to the treatment of attention deficit/hyperactivity disorder (ADHD) with mazindol. The latter can be administered as monotherapy or in combination with one or more compounds, including psychostimulants, for the indication of ADHD and associated or co-morbid symptoms.
    Type: Application
    Filed: October 9, 2020
    Publication date: April 1, 2021
    Inventor: Eric KONOFAL
  • PHACETOPERANE FOR TREATING OF ATTENTION DEFICIT HYPERACTIVITY DISORDER
    Publication number: 20200061044
    Abstract: The invention relates to the treatment of an attention deficit hyperactivity disorder (ADHD) with alpha-phenyl(piperidin-2-yl)methanol, or the pharmaceutically acceptable salts and esters thereof, in particular the acetate derivative, more particularly dextrophacetoperane. The invention additionally provides a method of synthesis of the (S,S) enantiomer of alpha-phenyl(piperidin-2-yl)methanol as well as a method of synthesis of dextrophacetoperane.
    Type: Application
    Filed: September 17, 2019
    Publication date: February 27, 2020
    Inventors: Eric KONOFAL, Bruno FIGADERE
  • Use of iron for treating attention deficit hyperactivity disorder in children
    Patent number: 10532100
    Abstract: The invention relates to the use of iron for preparing a medicament for the preventive and/or curative treatment of attention deficit hyperactivity disorder (ADHD) or at least one of the symptoms thereof, for a patient requiring such treatment.
    Type: Grant
    Filed: June 1, 2004
    Date of Patent: January 14, 2020
    Assignee: NLS PHARMA AG
    Inventor: Eric Konofal
  • MAZINDOL COMBINATION IN THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY
    Publication number: 20190328714
    Abstract: The present invention relates to the field of human health, and more particularly to the treatment of attention deficit/hyperactivity disorder (ADHD) with mazindol. The latter can be administered as monotherapy or in combination with one or more compounds, including psychostimulants, for the indication of ADHD and associated or co-morbid symptoms.
    Type: Application
    Filed: July 10, 2019
    Publication date: October 31, 2019
    Inventor: Eric KONOFAL
  • Phacetoperane for treating of attention deficit hyperactivity disorder
    Patent number: 10456387
    Abstract: The invention relates to the treatment of an attention deficit hyperactivity disorder (ADHD) with alpha-phenyl(piperidin-2-yl)methanol, or the pharmaceutically acceptable salts and esters thereof, in particular the acetate derivative, more particularly dextrophacetoperane. The invention additionally provides a method of synthesis of the (S,S) enantiomer of alpha-phenyl(piperidin-2-yl)methanol as well as a method of synthesis of dextrophacetoperane.
    Type: Grant
    Filed: March 6, 2018
    Date of Patent: October 29, 2019
    Assignee: NLS PHARMACEUTICS AG
    Inventors: Eric Konofal, Bruno Figadere
  • PHACETOPERANE FOR TREATING OF ATTENTION DEFICIT HYPERACTIVITY DISORDER
    Publication number: 20180214436
    Abstract: The invention relates to the treatment of an attention deficit hyperactivity disorder (ADHD) with alpha-phenyl(piperidin-2-yl)methanol, or the pharmaceutically acceptable salts and esters thereof, in particular the acetate derivative, more particularly dextrophacetoperane. The invention additionally provides a method of synthesis of the (S,S) enantiomer of alpha-phenyl(piperidin-2-yl)methanol as well as a method of synthesis of dextrophacetoperane.
    Type: Application
    Filed: March 6, 2018
    Publication date: August 2, 2018
    Inventors: Eric KONOFAL, Bruno FIGADERE
  • MAZINDOL COMBINATION IN THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY
    Publication number: 20170252325
    Abstract: The present invention relates to the field of human health, and more particularly to the treatment of attention deficit/hyperactivity disorder (ADHD) with mazindol. The latter can be administered as monotherapy or in combination with one or more compounds, including psychostimulants, for the indication of ADHD and associated or co-morbid symptoms.
    Type: Application
    Filed: May 22, 2017
    Publication date: September 7, 2017
    Inventor: Eric KONOFAL
  • MAZINDOL COMBINATION IN THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY
    Publication number: 20170216258
    Abstract: The present invention relates to the field of human health, and more particularly to the treatment of attention deficit/hyperactivity disorder (ADHD) with mazindol. The latter can be administered as monotherapy or in combination with one or more compounds, including psychostimulants, for the indication of ADHD and associated or co-morbid symptoms.
    Type: Application
    Filed: April 19, 2017
    Publication date: August 3, 2017
    Inventor: Eric KONOFAL
  • LAUFLUMIDE AND THE ENANTIOMERS THEREOF, METHOD FOR PREPARING SAME AND THERAPEUTIC USES THEREOF
    Publication number: 20170151197
    Abstract: The invention relates to the molecule having formula (I), as well as the enantiomers thereof, and to the use of same in the treatment of ADHD, narcolepsy or idiopathic hypersomnia.
    Type: Application
    Filed: December 8, 2016
    Publication date: June 1, 2017
    Inventor: Eric Konofal
  • Lauflumide and the enantiomers thereof, method for preparing same and therapeutic uses thereof
    Patent number: 9637447
    Abstract: The invention relates to the molecule having formula (I), as well as the enantiomers thereof, and to the use of same in the treatment of ADHD, narcolepsy or idiopathic hypersomnia.
    Type: Grant
    Filed: January 20, 2012
    Date of Patent: May 2, 2017
    Assignee: NLS Pharma AG
    Inventor: Eric Konofal
  • Mazindol Combination In The Treatment Of Attention-Deficit/Hyperactivity
    Publication number: 20160030394
    Abstract: The present invention relates to the field of human health, and more particularly to the treatment of attention deficit/hyperactivity disorder (ADHD) with mazindol. The latter can be administered as monotherapy or in combination with one or more compounds, including psychostimulants, for the indication of ADHD and associated or co-morbid symptoms.
    Type: Application
    Filed: October 15, 2015
    Publication date: February 4, 2016
    Applicant: Assistance Publique-Hopitaux de Paris
    Inventor: Eric Konofal
  • PHACETOPERANE FOR THE TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER
    Publication number: 20150038533
    Abstract: The invention relates to the treatment of an attention deficit hyperactivity disorder (ADHD) with alpha-phenyl(piperidin-2-yl)methanol, or the pharmaceutically acceptable salts and esters thereof, in particular the acetate derivative, more particularly dextrophacetoperane. The invention additionally provides a method of synthesis of the (S,S) enantiomer of alpha-phenyl(piperidin-2-yl)methanol as well as a method of synthesis of dextrophacetoperane.
    Type: Application
    Filed: November 29, 2012
    Publication date: February 5, 2015
    Inventors: Eric Konofal, Bruno Figadere
  • LAUFLUMIDE AND THE ENANTIOMERS THEREOF, METHOD FOR PREPARING SAME AND THERAPEUTIC USES THEREOF
    Publication number: 20130295196
    Abstract: The invention relates to the molecule having formula (I), as well as the enantiomers thereof, and to the use of same in the treatment of ADHD, narcolepsy or idiopathic hypersomnia.
    Type: Application
    Filed: January 20, 2012
    Publication date: November 7, 2013
    Applicant: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
    Inventor: Eric Konofal
  • MAZINDOL COMBINATION IN THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY
    Publication number: 20120308668
    Abstract: The present invention relates to the field of human health, and more particularly to the treatment of attention deficit/hyperactivity disorder (ADHD) with mazindol. The latter can be administered as monotherapy or in combination with one or more compounds, including psychostimulants, for the indication of ADHD and associated or co-morbid symptoms.
    Type: Application
    Filed: August 21, 2012
    Publication date: December 6, 2012
    Applicant: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
    Inventor: Eric Konofal
  • Mazindol combination in the treatment of attention deficit/hyperactivity
    Patent number: 8293779
    Abstract: The present invention relates to the field of human health, and more particularly to the treatment of attention deficit/hyperactivity disorder (ADHD) with mazindol. The latter can be administered as monotherapy or in combination with one or more compounds, including psychostimulants, for the indication of ADHD and associated or co-morbid symptoms.
    Type: Grant
    Filed: April 11, 2007
    Date of Patent: October 23, 2012
    Assignee: Assistance Publique-Hopitaux de Paris
    Inventor: Eric Konofal
  • Mazindol Combindation In The Treatment Of Attention Deficit/Hyperactivity
    Publication number: 20110223260
    Abstract: The present invention relates to the filed of human health, and more particularly to the treatment of attention deficit/hyperactivity disorder (ADHD) with mazindol. The latter can be administered as monotherapy or in combination with one or more compounds, including psychostimulants, for the indication of ADHD and associated or co-morbid symptoms.
    Type: Application
    Filed: April 11, 2007
    Publication date: September 15, 2011
    Inventor: Eric Konofal
  • Mazindol Combination In The Treatment Of Attention-Deficit/Hyperactivity
    Publication number: 20110183009
    Abstract: The present invention relates to the field of human health, and more particularly to the treatment of attention deficit/hyperactivity disorder (ADHD) with mazindol. The latter can be administered as monotherapy or in combination with one or more compounds, including psychostimulants, for the indication of ADHD and associated or co-morbid symptoms.
    Type: Application
    Filed: April 5, 2011
    Publication date: July 28, 2011
    Applicant: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
    Inventor: Eric Konofal
  • MAZINDOL COMBINATION IN THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY
    Publication number: 20090136593
    Abstract: The present invention relates to the field of human health, and more particularly to the treatment of attention deficit/hyperactivity disorder (ADHD) with mazindol. The latter can be administered as monotherapy or in combination with one or more compounds, including psychostimulants, for the indication of ADHD and associated or co-morbid symptoms.
    Type: Application
    Filed: April 11, 2007
    Publication date: May 28, 2009
    Inventor: Eric Konofal